Study record managers: refer to the Data Element Definitions if submitting registration or results information.
|1||NCT02032823||Recruiting||Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer||
||Industry / Other||
||1800||All||18 Years to 130 Years (Adult, Older Adult)||NCT02032823||D081CC00006
|OlympiA||April 22, 2014||November 30, 2020||November 27, 2028||January 10, 2014||April 8, 2019||